These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12538930)

  • 1. [Netherlands' experience in positron emission tomography in thoracic oncology].
    Hoekstra O
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S25-7. PubMed ID: 12538930
    [No Abstract]   [Full Text] [Related]  

  • 2. [Nuclear medicine in oncology: new diagnostic and therapeutic methods].
    Maublant J; Lumbroso J; Cachin F; Raoul JL; Syrota A; Vuillez JP
    Bull Cancer; 2001 Jan; 88(1):35-44. PubMed ID: 11182651
    [No Abstract]   [Full Text] [Related]  

  • 3. FDG-PET in clinical oncology: review of the literature and report of one institution's experience.
    Oehr P; Ruhlmann J; Biersack HJ
    J Investig Med; 1999 Nov; 47(9):452-61. PubMed ID: 10572375
    [No Abstract]   [Full Text] [Related]  

  • 4. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical PET in oncology.
    Biersack HJ; Bender H; Ruhlmann J; Oehr P; Guhlke S; Grünwald F
    Rev Esp Med Nucl; 2000 Jun; 19(3):219-24. PubMed ID: 11062087
    [No Abstract]   [Full Text] [Related]  

  • 6. [Positron emission tomography and gastrointestinal oncology].
    Ducreux M; Taieb J; Boige V; Lasser P; Elias D; Lumbroso J
    Gastroenterol Clin Biol; 2003 May; 27(5 Suppl):B71-8. PubMed ID: 12843940
    [No Abstract]   [Full Text] [Related]  

  • 7. Kinetic analysis of 18F-FLT PET in lung tumors.
    Bading JR
    J Nucl Med; 2012 Mar; 53(3):506; author reply 506-507. PubMed ID: 22294484
    [No Abstract]   [Full Text] [Related]  

  • 8. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in skin and ocular melanoma].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S42-6. PubMed ID: 12739335
    [No Abstract]   [Full Text] [Related]  

  • 9. [The role of positron emission tomography with C18-Fluorodeoxyglucose in clinical oncology].
    Granov AM; Tiushin LA; Tlostanova MS; Kostenikov NA; Ryzhkova DV; Savello VE; Stanzhevskiĭ AA
    Vopr Onkol; 2003; 49(5):563-73. PubMed ID: 14682126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The need for Health Technology Assessments of PET.
    Van Tinteren H; Hoekstra OS; Boers M
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1438-9; author reply 1439. PubMed ID: 12898206
    [No Abstract]   [Full Text] [Related]  

  • 11. Health technology assessment of PET in oncology: re Eur J Nucl Med Mol Imaging 2003; 30:637-641.
    Kristensen FB; Adams E; Briones E; Coburn D; Facey K; Hansen NW; Hoeksema J; Mørland B
    Eur J Nucl Med Mol Imaging; 2004 Feb; 31(2):295-7; author reply 297-8; discussion 298. PubMed ID: 15129712
    [No Abstract]   [Full Text] [Related]  

  • 12. FDG positron emission tomography in melanoma.
    Tecnologica MAP Suppl; 2000 Jan; ():11-3. PubMed ID: 10848117
    [No Abstract]   [Full Text] [Related]  

  • 13. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in cancer of the upper aerodigestive tract].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S67-79. PubMed ID: 12739338
    [No Abstract]   [Full Text] [Related]  

  • 14. Are health technology assessments a reliable tool in th analysis of the clinical value of PET in oncology? Who audits the auditors?
    Højgaard L
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):637-41. PubMed ID: 12838956
    [No Abstract]   [Full Text] [Related]  

  • 15. Patterns of lymphadenopathy in thoracic malignancies.
    Sharma A; Fidias P; Hayman LA; Loomis SL; Taber KH; Aquino SL
    Radiographics; 2004; 24(2):419-34. PubMed ID: 15026591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging of advanced cervical cancer.
    Querleu D; Delannes M; Leblanc E; Castelain B; Sonoda Y
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):614. PubMed ID: 15890608
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer.
    Reed CE; Harpole DH; Posther KE; Woolson SL; Downey RJ; Meyers BF; Heelan RT; MacApinlac HA; Jung SH; Silvestri GA; Siegel BA; Rusch VW;
    J Thorac Cardiovasc Surg; 2003 Dec; 126(6):1943-51. PubMed ID: 14688710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thoracic malignancies, cisplatin and renal function.
    Nortier J; Sculier JP
    Eur Respir J; 2011 Apr; 37(4):760-1. PubMed ID: 21454897
    [No Abstract]   [Full Text] [Related]  

  • 19. FDG positron emission tomography to manage patients with an occult primary carcinoma and metastasis outside the cervical lymph nodes.
    TEC Bull (Online); 2002 Jul; 19(2):14-8. PubMed ID: 12166472
    [No Abstract]   [Full Text] [Related]  

  • 20. [Positron emission tomography in thoracic radiography].
    Vaylet F; Foehrenbach H; Guigay J; de Dreuille O; Maszelin P; Grassin F; Margery J; Dot JM; Gaillard JF; L'Her P
    Cancer Radiother; 2000 Nov; 4 Suppl 1():13s-16s. PubMed ID: 11194952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.